2022 Clinic Disease Nuclear Medicine 
Imaging Technology
JUNE 27, 2023
Urbain, MD, PhD, FASNC , professor of radiology/nuclear medicine and medicine, vice chair of theranostics, and director of nuclear medicine at Roswell Park Cancer Center at the University of Buffalo , Buffalo, New York. and ‘How can we ensure diversity in all parts of the nuclear medicine family?’
AuntMinnie
OCTOBER 31, 2023
Fibroblast activation protein inhibitor (FAPI)-PET/CT appears superior to standard FDG-PET/CT for detecting gastrointestinal cancer, with higher radiotracer uptake seen in most tumors, according to a study published October 26 in the Journal of Nuclear Medicine. Image courtesy of the Journal of Nuclear Medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
MARCH 26, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman.
AuntMinnie
APRIL 4, 2024
They're also mindful of the multiple dedicated teams required to build a theranostics clinic properly. Hope, vice chair of clinical operations and strategy in the UCSF department of radiology, established the radioligand therapy group at the university. Theranostics is becoming a treatment option for a larger volume of cancer patients.
AuntMinnie
JANUARY 26, 2024
In a comparative imaging trial, fibroblast activation protein inhibitor (FAPI)-PET/CT outperformed FDG-PET/CT in detecting primary tumors in patients with head and neck cancer, according to a study published January 25 in the Journal of Nuclear Medicine. Image courtesy of the Journal of Nuclear Medicine.
Imaging Technology
JUNE 29, 2023
christine.book Thu, 06/29/2023 - 12:17 June 29, 2023 — A study presented this week during the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, SNMMI 2023 , found that personalized dosing of men with prostate cancer resulted in improved patient outcomes. Approved by the U.S. Patients at St.
AuntMinnie
JUNE 20, 2024
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Traditional treatments didn't slow the disease in these patients, noted UT’s Vroman.
Expert insights. Personalized for you.
115 
Let's personalize your content